home

Cydan, NEA’s Orphan Drug Accelerator, Targets Sickle Cell With Startup Imara

Frontierxconomy2016-04-15 17:04 Read   63

Cydan Development, New Enterprise Associates’s orphan drug startup accelerator, has taken a look at around 600 assets since it was formed some three years ago. Sifting through all these potential drugs for diamonds in the rough has been an exhaustive process, perhaps even more so than the firm’s executives expected.

U.S. Drug Spending Climbs

EVENTSwsj2016-04-15 14:09 Read   97

Growth rate slows but remains at high level, fueled by pricey new medications

Exclusive: Lonza in bid to acquire Catalent - sources

EVENTSreuters2016-04-15 14:02 Read   58

Swiss specialty chemicals and life sciences company Lonza Group AG (LONN.S) has offered to acquire U.S. drug delivery technology company Catalent Inc (CTLT.N), three people familiar with the matter said this week.

Allergan’s Actavis recalls nearly 600,000 bottles of ADHD drug

Commentsfiercepharma2016-04-15 13:45 Read   79

Teva ($TEVA) is expecting to close on its buyout of Allergan’s generic drug business, but for now Actavis is still Allergan’s, for better or worse. That means that Allergan ($AGN) is responsible for the recall of more than 50 lots, consisting of nearly 600,000 bottles, of its copy of the ADHD drug Adderall.

Hundreds in China to be punished over tainted vaccines

Regulatormarketwatch2016-04-15 13:45 Read   86

BEIJING — China will punish 357 officials implicated in the sale of improperly handled vaccines, a scandal that has reignited drug safety fears and further eroded trust in the country’s public health system.

AZ, BMS get a breather as India yanks CL appeals

EVENTSReuters2016-04-15 13:37 Read   303

Compulsory license applications in India for Sprycel (dasatinib) from Bristol-Myers Squibb ($BMS) and Onglyza (saxagliptin) from AstraZeneca ($AZN) have been quietly withdrawn as firms in the space suggest at least a higher bar has been set.

China genomics giant BGI targets A-share IPO

EVENTSfinanceasia2016-04-15 13:27 Read   189

BGI, one of the world’s largest genome sequencing companies, is targeting an A-share Chinese listing to help raise capital for development and acquisitions, some of them overseas.

Tobira Therapeutics and Dong-A ST Enter Into License Agreements for Evogliptin and Cenicriviroc

Frontierprnewswire2016-04-15 13:23 Read   97

Tobira Therapeutics, Inc. and Dong-A ST Co., Ltd., today announced that the companies have entered into two separate licensing agreements.

CardioBrief: Diet Drug Loses Another Cardiovascular Outcomes Trial

Healthmedpagetoday2016-04-15 13:17 Read   99

In a further sign of the chaos surrounding weight-loss drug naltrexone/bupropion (Contrave), drugmaker Orexigen has again terminated an FDA-mandated cardiovascular outcomes trial with the drug.

Roche clears drug that caused vision loss in India

EVENTSswissinfo2016-04-15 11:21 Read   89

An internal enquiry by the Swiss pharma giant Roche has revealed no quality problems with its anti-cancer drug Avastin, which resulted in vision loss in 15 patients in India. The drug was being used to treat eye problems without regulatory approval. 

Continuous Manufacturing Has a Strong Impact on Drug Quality

RegulatorFDA2016-04-15 11:15 Read   127

If we used a time machine to transport a pharmaceutical scientist from the 1960s into a current pharmaceutical production plant of today, it might be surprising to learn that they would already be very familiar with most of the processes and production techniques being used. That’s because not much has changed in pharmaceutical production over the last 50 or so years.

Touts thwart top-level reforms at China's public hospitals

Frontierfiercepharma2016-04-15 11:02 Read   90

China's repeated efforts to reform the public hospital system by getting patients to smaller clinics first and curbing graft in a system under intense demand and supply strains has met its match in swarms of touts who promise quick appointments in exchange for cash.